Best Peptides for Fat Loss Without Muscle Loss (Body Recomposition)

By NorthPeptide Research Team  |  April 16, 2026

Why Body Recomposition Is Biologically Hard

The challenge of losing fat while maintaining muscle mass — what fitness researchers call “body recomposition” — is not a failure of willpower. It is a consequence of how mammalian metabolism evolved. When caloric intake falls below expenditure, the body activates a coordinated hormonal response designed to conserve energy and protect survival: metabolic rate declines, appetite hormones surge, and protein catabolism (muscle breakdown) increases to provide gluconeogenic substrate.

Several mechanisms make simultaneous fat loss and muscle retention difficult:

• Insulin suppression: Caloric restriction reduces insulin, which is both anti-lipolytic (it inhibits fat mobilization) and anabolic (it promotes protein synthesis in muscle). Lower insulin promotes fat mobilization, but also reduces the anabolic drive for muscle protein synthesis.
• GH/IGF-1 decline: Caloric restriction in the context of energy deprivation reduces IGF-1, reducing the anabolic signal for muscle maintenance.
• Cortisol elevation: The stress of caloric deficit elevates cortisol, which is directly catabolic to muscle protein.
• Appetite hormone dysregulation: GLP-1, ghrelin, and leptin all shift in ways that increase hunger during restriction, driving compensatory food intake that ends the deficit.

Research peptides have attracted interest in body recomposition contexts precisely because some of them appear to address these mechanisms selectively — promoting fat mobilization or muscle retention through pathways that caloric restriction alone does not activate efficiently. This article reviews the compounds with the most relevant published evidence.

The Six Compounds Most Studied for Recomposition

1. Semaglutide — Appetite Suppression and Metabolic Regulation

Semaglutide is a GLP-1 receptor agonist — it mimics the action of glucagon-like peptide-1, an incretin hormone secreted by the gut in response to food. GLP-1 receptor activation in the central nervous system (particularly the hypothalamus and brainstem) produces sustained appetite suppression and reduces food reward signaling. Peripheral effects include slowed gastric emptying (prolonging satiety) and improved insulin secretion dynamics.

The STEP clinical trial program established semaglutide 2.4 mg weekly as producing approximately 15% body weight reduction at 68 weeks in adults with obesity. DEXA analysis from these trials revealed that approximately 75–80% of the weight lost was fat mass, with lean mass accounting for 20–25% of total weight loss — a ratio somewhat better than caloric restriction alone, but still involving meaningful muscle loss in absolute terms (Wilding et al., 2021, NEJM, PubMed 33755728).

The lean mass loss observed with semaglutide — and all GLP-1 agonists — has become a major research focus. Hypotheses for why GLP-1 agonists cause muscle loss include: reduced protein intake due to appetite suppression, reduced exercise capacity due to weight loss fatigue, and possible direct effects on muscle protein synthesis through GLP-1 receptors in skeletal muscle. This is an active area of investigation, with combination approaches (GLP-1 agonist + resistance exercise + protein optimization) being studied to mitigate lean mass loss.

View Semaglutide →

2. Retatrutide — Triple Agonist with Greater Metabolic Breadth

Retatrutide is a triple agonist of GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors — sometimes called a “triagonist.” Its advantage over semaglutide in the context of body recomposition is its glucagon receptor activity: glucagon stimulates hepatic lipid oxidation, increases basal metabolic rate, and activates adipose tissue lipolysis through cAMP-mediated pathways. This metabolic rate elevation partially compensates for the metabolic adaptation that typically accompanies caloric restriction.

Phase II clinical trial data published in 2023 showed retatrutide produced approximately 17.5% body weight reduction at 24 weeks in a dose-response study — with higher doses suggesting continued loss trajectories that could exceed 20–25% at 48 weeks (Jastreboff et al., 2023, NEJM, PubMed 37356314). Importantly, the glucagon agonism component raises the theoretical possibility of better fat-to-lean mass loss ratios than GLP-1-only agonists, though this has not been definitively demonstrated with retatrutide specifically. Phase III trials are ongoing.

The glucagon component also raises HDL cholesterol and reduces hepatic fat — effects with potential relevance for the metabolic context in which recomposition research is typically conducted.

View Retatrutide →

3. AOD-9604 — Fat-Specific Lipolysis Without IGF-1

AOD-9604 is a modified fragment of human growth hormone (amino acids 176–191 with an N-terminal tyrosine addition) designed specifically to isolate GH’s lipolytic activity from its growth-promoting and IGF-1-elevating effects. This separation is directly relevant to body recomposition: pure lipolysis without IGF-1 elevation means fat mobilization without the insulin resistance, glucose disruption, or tissue growth associated with full-length GH administration.

The mechanism involves beta-3 adrenergic receptor activation in adipose tissue, stimulating hormone-sensitive lipase and adipose triglyceride lipase. Research has shown preferential activity on visceral adipose tissue over subcutaneous depots — a metabolically favorable distribution, as visceral fat is more strongly linked to insulin resistance and cardiovascular risk factors.

Phase IIb clinical trial data (300 subjects, 12 weeks, oral administration) demonstrated statistically significant fat-specific weight loss at the 1 mg dose, with no changes in blood glucose, insulin, IGF-1, or other metabolic parameters — confirming the mechanistic separation from GH’s metabolic effects. The absence of lean mass changes in the clinical trial is consistent with AOD-9604’s mechanism: it promotes fat mobilization without anabolic or catabolic effects on muscle.

For body recomposition research specifically, AOD-9604 is notable for what it does not do: it does not suppress appetite (so caloric intake is not necessarily reduced, making it relevant for protocols studying isolated adipose effects), it does not elevate IGF-1, and it does not cause the fluid retention or glucose disruption of GH therapy.

View AOD-9604 →

4. Tesamorelin — Visceral Fat Reduction via GHRH Stimulation

Tesamorelin is a GHRH (growth hormone-releasing hormone) analog — the only one with FDA approval, for HIV-associated lipodystrophy (excess abdominal fat). Its mechanism is physiological: it stimulates the pituitary to produce growth hormone in its natural pulsatile pattern, rather than introducing exogenous GH. This pulsatility is important because the ratio of lipolytic to anabolic GH effects is regulated by pulse characteristics — pulsatile GH preferentially activates lipolysis, while continuous GH exposure produces more pronounced anabolic and glucose-dysregulating effects.

The pivotal FDA approval trials demonstrated 15–18% reduction in trunk fat area (CT scan) at 26 weeks, with visceral adipose tissue (VAT) preferentially reduced. These are clinically meaningful reductions in a metabolically important fat depot. Lean mass was preserved in these trials — tesamorelin’s stimulation of pulsatile GH provides the anabolic signaling that supports muscle protein synthesis while simultaneously promoting lipolysis (Falutz et al., 2010, Annals of Internal Medicine, PubMed 20818905).

The body recomposition relevance is significant: tesamorelin is one of the few compounds with clinical data showing visceral fat reduction without lean mass loss, through a physiological mechanism that preserves the GH axis’s self-regulating feedback. The modest elevations in fasting glucose observed with long-term use reflect GH’s known diabetogenic properties and should be monitored in research protocols.

View Tesamorelin →

5. CJC-1295 + Ipamorelin — GH Pulsatility for Lean Mass Preservation

CJC-1295 (a DPP-IV-resistant GHRH analog) and Ipamorelin (a selective ghrelin mimetic acting at the GHS-R1a receptor) are frequently combined in research because they stimulate GH release through complementary, non-redundant receptor pathways. CJC-1295 acts at the GHRH receptor via cAMP/PKA signaling; Ipamorelin acts at GHS-R1a via phospholipase C/calcium signaling. The combination produces synergistic GH output that exceeds the sum of individual responses.

In body recomposition research contexts, the combination is relevant primarily for its muscle-preservation potential. Growth hormone is a key regulator of muscle protein turnover — it stimulates IGF-1 production in muscle tissue (autocrine/paracrine IGF-1), promotes collagen synthesis for connective tissue integrity, and supports the tissue repair processes that follow resistance exercise. Restoring GH pulsatility in contexts of age-related decline or caloric restriction may preserve the anabolic drive needed to maintain lean mass during a fat loss protocol.

A 2006 human clinical study of CJC-1295 (DAC formulation) documented 2–10x increases in mean GH concentration and 1.5–3x IGF-1 elevation lasting 9–11 days following a single dose, confirming the potency of GHRH analog-mediated GH stimulation. Ipamorelin’s selectivity — no significant effects on cortisol, prolactin, or appetite — makes it particularly useful in combination research where hormonal confounders need to be minimized.

The combination is studied as a lean mass preservation strategy, not as a primary fat loss agent. In recomposition research, it is more appropriately positioned as addressing the muscle side of the equation while other agents or caloric management address the fat side.

View CJC-1295 + Ipamorelin →

6. AICAR — The Exercise Mimetic

AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) is a cell-permeable precursor of ZMP, an AMP analog that activates AMP-activated protein kinase (AMPK) — the cellular energy sensor that responds to low energy states. AMPK activation produces effects that closely mimic the metabolic adaptations of endurance exercise:

• Enhanced fat oxidation: AMPK phosphorylates and inhibits acetyl-CoA carboxylase (ACC), reducing malonyl-CoA levels and lifting the inhibition on carnitine palmitoyltransferase I (CPT1) — the rate-limiting step for fatty acid entry into mitochondria. This increases fat oxidation even at rest.
• Glucose uptake: AMPK promotes GLUT4 translocation to the muscle cell membrane, increasing glucose uptake independently of insulin.
• Mitochondrial biogenesis: AMPK activates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), which drives mitochondrial biogenesis and increases oxidative capacity — the same adaptation produced by endurance training.
• Protein synthesis modulation: AMPK inhibits mTORC1 (mechanistic target of rapamycin complex 1) under energy-stress conditions. In the context of caloric restriction, this is a double-edged effect: AMPK’s metabolic benefits come at the cost of reduced anabolic signaling. This is why AICAR is studied more as a metabolic enhancer than as a muscle-building agent.

The “exercise in a pill” characterization comes from a landmark 2008 study in Cell that showed AICAR treatment in sedentary mice improved running endurance by 44% and increased the proportion of oxidative (slow-twitch, fatigue-resistant) muscle fibers — changes normally requiring weeks of endurance training (Narkar et al., 2008, Cell, PubMed 18674809). Human data on AICAR is limited compared to the animal literature. Its AMPK-activating mechanism is well-validated, but the optimal research protocols for body composition endpoints in human models have not been established.

7. Follistatin — Myostatin Inhibition for Muscle Preservation

Follistatin is an endogenous glycoprotein that functions as a binding protein and antagonist of activin and myostatin. Myostatin (GDF-8) is a member of the TGF-β superfamily that acts as a negative regulator of skeletal muscle mass — animals with myostatin gene knockouts develop dramatically increased muscle mass (“double-muscling”), while myostatin overexpression causes muscle wasting. Follistatin binds myostatin with high affinity, preventing it from activating its receptors (ActRIIB) on muscle cells.

The relevance to body recomposition is direct: by reducing myostatin’s inhibitory influence on muscle protein synthesis and satellite cell activation, follistatin research aims to support muscle mass during periods of caloric deficit or in aging models where myostatin-mediated atrophy is accelerated.

Animal studies have demonstrated significant muscle hypertrophy following follistatin overexpression or administration. Gene therapy trials using follistatin-encoding vectors in Duchenne muscular dystrophy have produced measurable increases in muscle volume in some patients, providing proof-of-concept for follistatin’s anabolic mechanism in humans (Mendell et al., 2015, Molecular Therapy, PubMed 25965542).

Recombinant follistatin protein for research applications has a more limited evidence base than the genetic approaches, and its pharmacokinetics (including the degree of systemic myostatin inhibition achievable with subcutaneous administration) require further characterization. The theoretical concern with systemic myostatin inhibition — possible off-target effects on cardiac muscle, bone density, and follicle-stimulating hormone regulation (follistatin also binds activin, which regulates FSH) — should be considered in research design.

Comparison Table

The Research Design Challenge

Studying body recomposition in controlled research conditions presents several challenges that explain why clean combination data is scarce:

• Caloric control: Most recomposition research requires precise dietary control to separate compound effects from dietary effects. Ad libitum feeding studies conflate appetite suppression with direct metabolic effects.
• Measurement timing: DEXA scans, MRI, and CT provide the best body composition data but are expensive and not always available in all research settings. Surrogate measures (weight, circumference) cannot distinguish fat from lean mass changes.
• Training status: Resistance exercise is independently the most effective intervention for preserving muscle during caloric restriction. Isolating peptide effects from training effects requires controlled exercise protocols.
• Combination effects: Some of these compounds address complementary mechanisms (e.g., fat mobilization + muscle preservation) that might synergize in body recomposition — but combination studies have not been conducted with most of these pairings under controlled conditions. Unknown interaction effects must be considered.

What the Evidence Supports — and What It Does Not

The most honest summary of what the research supports for each compound’s role in body recomposition:

• Semaglutide and Retatrutide produce the largest documented fat loss effects, but some lean mass loss occurs. The fat-to-lean loss ratio may be improved with adequate protein intake and resistance training, though this has not been optimized in controlled trials.
• AOD-9604 has the clearest mechanistic separation of fat loss from muscle effects, and the clinical safety data is strong. Effect sizes are smaller than GLP-1 agonists, but the lack of interference with muscle metabolism is a meaningful advantage for recomposition research.
• Tesamorelin has the best evidence for visceral fat reduction with lean mass preservation, derived from a large FDA-approval trial program. Its physiological mechanism (pulsatile GH restoration) makes theoretical sense for recomposition.
• CJC-1295 + Ipamorelin are best understood as lean mass support tools — they do not produce direct fat loss of the magnitude seen with GLP-1 agonists, but their GH-stimulating effects may mitigate muscle loss in caloric deficit protocols.
• AICAR has compelling animal data for fat oxidation enhancement but limited human trials. Its AMPK mechanism is well-validated but the practical effect size in human body composition studies is not established.
• Follistatin has the strongest theoretical basis for muscle preservation through myostatin inhibition, but protein-form pharmacokinetics in research settings are not well-characterized compared to the gene therapy applications.